MARKET

ONC

ONC

BeOne Medicines Ltd.
NASDAQ
286.65
+9.70
+3.50%
Opening 10:36 03/27 EDT
OPEN
285.89
PREV CLOSE
276.95
HIGH
289.60
LOW
284.97
VOLUME
61.38K
TURNOVER
--
52 WEEK HIGH
385.22
52 WEEK LOW
196.45
MARKET CAP
31.80B
P/E (TTM)
113.34
1D
5D
1M
3M
1Y
5Y
1D
BeOne Medicines Price Target Announced at $340.00/Share by Wolfe Research
Dow Jones · 8h ago
BeOne Medicines Initiated at Outperform by Wolfe Research
Dow Jones · 8h ago
Wolfe Research Initiates Coverage On BeOne Medicines with Outperform Rating, Announces Price Target of $340
Benzinga · 9h ago
Buy Rating on BeOne Medicines: Strong Brukinsa Positioning, Deep Oncology Pipeline, and Attractive Valuation Ahead of 2026 Milestones
TipRanks · 1d ago
BeOne Medicines initiated with an Outperform at Wolfe Research
TipRanks · 1d ago
BeOne Medicines Advances Combo Cancer Pill With Completed Phase 1 Bioavailability Study
TipRanks · 2d ago
If You Invested $100 In BeOne Medicines Stock 10 Years Ago, You Would Have This Much Today
Benzinga · 2d ago
BeOne Medicines FY2025 revenue rises 40.2% to US$5.3 billion; net income climbs to US$286.9 million
Reuters · 2d ago
More
About ONC
BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.

Webull offers BeOne Medicines AG (ADR) stock information, including NASDAQ: ONC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ONC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ONC stock methods without spending real money on the virtual paper trading platform.